These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer. Lampropoulou DI; Aravantinos G; Katifelis H; Lazaris F; Laschos K; Theodosopoulos T; Papadimitriou C; Gazouli M Cancer Biomark; 2019; 25(2):213-221. PubMed ID: 31045514 [TBL] [Abstract][Full Text] [Related]
24. Colorectal cancer: pharmacogenetics support for the correct drug prescription. Olivera G; Sendra L; Herrero MJ; Puig C; Aliño SF Pharmacogenomics; 2019 Jul; 20(10):741-763. PubMed ID: 31368847 [TBL] [Abstract][Full Text] [Related]
25. The role of pharmacogenetics in adjuvant treatment of non-small cell lung cancer. Danesi R; Pasqualetti G; Giovannetti E; Del Tacca M J Thorac Oncol; 2007 May; 2(5 Suppl):S27-30. PubMed ID: 17457227 [TBL] [Abstract][Full Text] [Related]
26. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer. Bhushan S; McLeod H; Walko CM Clin Colorectal Cancer; 2009 Jan; 8(1):15-21. PubMed ID: 19203892 [TBL] [Abstract][Full Text] [Related]
27. Tailored chemotherapy for colorectal cancer: a new approach to therapy. Iqbal S; Stoehlmacher J; Lenz HJ Cancer Invest; 2004; 22(5):762-73. PubMed ID: 15581057 [TBL] [Abstract][Full Text] [Related]
28. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients. Ruzzo A; Graziano F; Canestrari E; Magnani M Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793 [TBL] [Abstract][Full Text] [Related]
29. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954 [TBL] [Abstract][Full Text] [Related]
30. Implementing prognostic and predictive biomarkers in CRC clinical trials. Van Schaeybroeck S; Allen WL; Turkington RC; Johnston PG Nat Rev Clin Oncol; 2011 Feb; 8(4):222-32. PubMed ID: 21321566 [TBL] [Abstract][Full Text] [Related]
31. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. To KK; Leung WW; Ng SS Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386 [TBL] [Abstract][Full Text] [Related]
32. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Bosch TM Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231 [TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives. Benhaim L; Labonte MJ; Lenz HJ Scand J Gastroenterol; 2012 Mar; 47(3):325-39. PubMed ID: 22182673 [TBL] [Abstract][Full Text] [Related]
34. Pharmacoproteomic characterisation of human colon and rectal cancer. Frejno M; Zenezini Chiozzi R; Wilhelm M; Koch H; Zheng R; Klaeger S; Ruprecht B; Meng C; Kramer K; Jarzab A; Heinzlmeir S; Johnstone E; Domingo E; Kerr D; Jesinghaus M; Slotta-Huspenina J; Weichert W; Knapp S; Feller SM; Kuster B Mol Syst Biol; 2017 Nov; 13(11):951. PubMed ID: 29101300 [TBL] [Abstract][Full Text] [Related]
35. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Lentz F; Tran A; Rey E; Pons G; Tréluyer JM Am J Pharmacogenomics; 2005; 5(1):21-33. PubMed ID: 15727486 [TBL] [Abstract][Full Text] [Related]
37. Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update. Xie P; Mo JL; Liu JH; Li X; Tan LM; Zhang W; Zhou HH; Liu ZQ Cell Oncol (Dordr); 2020 Dec; 43(6):989-1001. PubMed ID: 32474853 [TBL] [Abstract][Full Text] [Related]
38. Predictive markers for colorectal cancer: current status and future prospects. Longley DB; McDermott U; Johnston PG Clin Colorectal Cancer; 2003 Feb; 2(4):223-30. PubMed ID: 12620141 [TBL] [Abstract][Full Text] [Related]
39. Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy. Han Y; Cai H; Ma L; Ding Y; Tan X; Liu Y; Su T; Yu Y; Chang W; Zhang H; Fu C; Cao G Eur J Cancer; 2013 Nov; 49(16):3420-30. PubMed ID: 23809767 [TBL] [Abstract][Full Text] [Related]
40. Genetic variants in the glutathione S-transferase genes and survival in colorectal cancer patients after chemotherapy and differences according to treatment with oxaliplatin. Kap EJ; Richter S; Rudolph A; Jansen L; Ulrich A; Hoffmeister M; Ulrich CM; Brenner H; Chang-Claude J Pharmacogenet Genomics; 2014 Jul; 24(7):340-7. PubMed ID: 24842074 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]